Search
Tinidazole
go.drugbank.com/drugs/DB00911ApprovedInvestigationalA nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEtrolizumab
go.drugbank.com/drugs/DB12189Investigational[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as … [A244564, A244569, A244574, A244584] Etrolizumab is currently under investigation for the treatment of ulcerative colitis and Crohn's disease.
Categories: Integrin Receptor AntagonistEquine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalBesides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Categories: Biologics for Rheumatoid Arthritis TreatmentPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.
Categories: Sphingosine 1-phosphate Receptor Modulator, Sphingosine 1 Phosphate Receptor ModulatorsEteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalEteplirsen was the first treatment for DMD approved by the FDA.[A244925] … Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitorsGentian violet cation
go.drugbank.com/drugs/DB00406ApprovedA dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseSepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria.
Cresol
go.drugbank.com/drugs/DB11143ApprovedAt concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.